Category - Markets

Markets

Stifel ups Protagonist Therapeutics to buy; PT up to $17 from $11

Stifel upgraded Protagonist Therapeutics (NASDAQ:PTGX) to “buy” from “neutral” and raised its price target to $17 from $11 after expansion of a deal with Janssen for PTG-200 and other IL-23 receptor antagonists. The...

May 9, 2019

Markets

Canaccord cuts OraSure to hold; PT down to $10 from $16

Canaccord Genuity downgraded OraSure Technologies (NASDAQ:OSUR) to “hold” from “buy” and dropped its price target to $10 from $16, citing disappointment of underlying trends in direct-to-consumer (DTC) genetic testing...

May 9, 2019

Markets

HCW adjusts ReWalk Robotics PT to $4

H.C. Wainwright adjusted its price target for ReWalk Robotics (NASDAQ:RWLK) to $4 from 25 cents, citing a potential mid-2019 launch of the company’s ReStoresoft exosuit for rehabilitation of stroke patients in U.S. and...

May 8, 2019

Markets

ContraVir Pharma receives positive NASDAQ listing decision

The Nasdaq Hearings Panel granted ContraVir Pharmaceuticals’ (NASDAQ:CTRV) request for continued listing on The Nasdaq Capital Market, subject to compliance with certain conditions.

May 6, 2019

Markets

SVB Leerink starts Aclaris Therapeutics at OP; PT $13

SVB Leerink initiated coverage of Aclaris Therapeutics (NASDAQ:ACRS) with an “outperform” rating and $13 price target. The stock closed at $6.34 on May 3.

May 6, 2019

Markets

HCW ups ImmunoGen to buy from neutral; PT to $7 from $3.50

H.C. Wainwright upgraded ImmunoGen (NASDAQ:IMGN) to ”buy” from “neutral” with a $7 price target, saying that a potential green light for accelerated approval sets up a compelling risk reward scenario. The stock closed...

May 6, 2019

Markets

BTIG ups Voyager Therapeutics PT to $31 from $23

BTIG raised its price target for Voyager Petroleums (NASDAQ:VYGR) to $31 from $23 after the company reported positive data from eight patients with Parkinson’s disease in a Phase 1 trial to evaluate the safety and...

May 6, 2019

Markets

Roth starts LogicBio Therapeutics at buy; PT $26

Roth Capital Partners initiated coverage of LogicBio Therapeutics (NASDAQ:LOGC) with a “buy” rating and $26 price target. The stock closed at $13.61 on April 30.

May 1, 2019

Markets

Mackie starts Medicenna Therapeutics at speculative buy; PT $1.50

Mackie Research launched coverage of Medicenna Therapeutics (TSX:MDNA) with a “speculative buy” rating and a 12-month target price of $1.50. The stock closed at 68 cents on April 29.

April 30, 2019

Markets

Roth starts Zynerba Pharma at buy; PT $36

Roth Capital Partners initiated coverage of Zynerba Pharmaceuticals (NASDAQ:ZYNE) with a “buy” rating and $36 price target. The stock closed at $11.56 on April 29

April 30, 2019

Category - Markets

Stifel ups Protagonist Therapeutics to buy; PT up to $17 from $11

Canaccord cuts OraSure to hold; PT down to $10 from $16

HCW adjusts ReWalk Robotics PT to $4

ContraVir Pharma receives positive NASDAQ listing decision

SVB Leerink starts Aclaris Therapeutics at OP; PT $13

HCW ups ImmunoGen to buy from neutral; PT to $7 from $3.50

BTIG ups Voyager Therapeutics PT to $31 from $23

Roth starts LogicBio Therapeutics at buy; PT $26

Mackie starts Medicenna Therapeutics at speculative buy; PT $1.50

Roth starts Zynerba Pharma at buy; PT $36

General

More